These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23873598)

  • 1. Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma.
    Lamm W; Drach J; Kiesewetter B; Zielinksi CC; Mayerhöfer ME; Müllauer L; Raderer M
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1771-5. PubMed ID: 23873598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma.
    Woehrer S; Hejna M; Skrabs C; Drach J; Zielinski CC; Jaeger U; Raderer M
    Oncology; 2005; 69(6):499-502. PubMed ID: 16424679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
    Lamm W; Kaufmann H; Raderer M; Hoffmann M; Chott A; Zielinski C; Drach J
    Haematologica; 2011 Jul; 96(7):1008-14. PubMed ID: 21486866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
    Houot R; Le Gouill S; Ojeda Uribe M; Mounier C; Courby S; Dartigeas C; Bouabdallah K; Alexis Vigier M; Moles MP; Tournilhac O; Arakelyan N; Rodon P; El Yamani A; Sutton L; Fornecker L; Assouline D; Harousseau JL; Maisonneuve H; Caulet-Maugendre S; Gressin R;
    Ann Oncol; 2012 Jun; 23(6):1555-61. PubMed ID: 22012966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
    Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O;
    Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
    Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
    J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.
    Rodríguez J; Gutierrez A; Palacios A; Navarrete M; Blancas I; Alarcón J; Caballero MD; De Mattos SF; Gines J; Martínez J; Lopez A
    Leuk Lymphoma; 2007 Nov; 48(11):2172-8. PubMed ID: 17990179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
    Witzig TE; Johnston PB; LaPlant BR; Kurtin PJ; Pederson LD; Moore DF; Nabbout NH; Nikcevich DA; Rowland KM; Grothey A
    Am J Hematol; 2017 Oct; 92(10):1004-1010. PubMed ID: 28614905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
    Garbo LE; Flynn PJ; MacRae MA; Rauch MA; Wang Y; Kolibaba KS
    Invest New Drugs; 2009 Oct; 27(5):476-81. PubMed ID: 18953490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
    Fischer L; Jiang L; Dürig J; Schmidt C; Stilgenbauer S; Bouabdallah K; Solal-Celigny P; Scholz CW; Feugier P; de Wit M; Trappe RU; Hallek M; Graeven U; Hänel M; Hoffmann M; Delwail V; Macro M; Greiner J; Giagounidis AAN; Dargel B; Durot E; Foussard C; Silkenstedt E; Weigert O; Pott C; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Ribrag V; Dreyling M
    Leukemia; 2024 Jun; 38(6):1307-1314. PubMed ID: 38678093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.
    Obrador-Hevia A; Serra-Sitjar M; Rodríguez J; Belayachi L; Bento L; García-Recio M; Sánchez JM; Villalonga P; Gutiérrez A; Fernández de Mattos S
    Br J Haematol; 2016 Sep; 174(6):899-910. PubMed ID: 27220900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
    Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
    Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.
    Machover D; Delmas-Marsalet B; Misra SC; Ulusakarya A; Gumus Y; Frénoy N; Guettier C; Saffroy R; Innominato P; Almohamad W; Brahimi N; Haydar M; Goldschmidt E
    Biomed Pharmacother; 2010 Feb; 64(2):83-7. PubMed ID: 20044233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
    Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
    Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
    Igarashi T; Kobayashi Y; Ogura M; Kinoshita T; Ohtsu T; Sasaki Y; Morishima Y; Murate T; Kasai M; Uike N; Taniwaki M; Kano Y; Ohnishi K; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
    Ann Oncol; 2002 Jun; 13(6):928-43. PubMed ID: 12123339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
    El Gnaoui T; Dupuis J; Belhadj K; Jais JP; Rahmouni A; Copie-Bergman C; Gaillard I; Diviné M; Tabah-Fisch I; Reyes F; Haioun C
    Ann Oncol; 2007 Aug; 18(8):1363-8. PubMed ID: 17496309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.